Search Within

Jose T Baselga

Formats
  1. Meeting Abstract (241)
  2. Journal Article (233)
  3. Conference Paper (4)
  4. Research Letter (3)
  5. Book Section (2)
  6. Review (1)
Groups
  1. Department of Medicine (197)
  2. Solid Tumor Oncology Division (192)
  3. Breast Medicine Service (149)
  4. GSK Faculty (128)
  5. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (108)
  6. Human Oncology and Pathogenesis Program (97)

More Groups

People
  1. David Hyman (68)
  2. Maurizio Scaltriti (63)
  3. Clifford Hudis (57)
  4. Michael Berger (56)
  5. Larry Norton (51)
  6. Sarat Chandarlapaty (48)

More People

Years
  1. 2021 (5)
  2. 2020 (11)
  3. 2019 (25)
  4. 2018 (58)
  5. 2017 (68)
  6. 2016 (67)

More Years

Publications
  1. Cancer Research (109)
  2. Journal of Clinical Oncology (92)
  3. Annals of Oncology (29)
  4. Clinical Cancer Research (29)
  5. European Journal of Cancer (25)
  6. Cancer Discovery (13)

More Publications

Publishers
  1. American Association for Cancer Research (163)
  2. American Society of Clinical Oncology (97)
  3. Oxford University Press (41)
  4. Elsevier Inc. (39)
  5. Nature Publishing Group (30)
  6. Springer (16)

More Publishers

Results (484)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Research-Based PAM50 subtype predictor identifies higher responses and improved survival outcomes in HER2- Positive breast cancer in the NOAH Study
    Journal Article

    Prat, A.; Bianchini, G.; Thomas, M.; Belousov, A.; Cheang, M. C. U.; Koehler, A.; Gómez, P.; Semiglazov, V.; Eiermann, W.; Tjulandin, S.; more...
    Clinical Cancer Research (2014)

    Fulltext@MSK | Save
  • Potential biomarkers of long-term benefit from single-agent trastuzumab or lapatinib in HER2-positive metastatic breast cancer
    Journal Article

    Montemurro, F.; Prat, A.; Rossi, V.; Valabrega, G.; Sperinde, J.; Peraldo-Neia, C.; Donadio, M.; Galván, P.; Sapino, A.; Aglietta, M.; more...
    Molecular Oncology (2014)

    Fulltext@MSK | Save
  • Assessment of genetic alterations in postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer from the BOLERO-2 trial by next-generation sequencing
    Meeting Abstract

    Piccart, M.; Rugo, H.; Chen, D.; Campone, M.; Burris, H. A.; Taran, T.; Sahmoud, T.; Deleu, I.; Hortobagyi, G.; Baselga, J.
    Annals of Oncology (2013)

    Fulltext@MSK | Save
  • Freedom from progression (FFP) by adding paclitaxel (T) to doxorubicin (A) followed by CMF as adjuvant or primary systemic therapy: 10-yr results of a randomized phase III European Cooperative Trial in Operable Breast Cancer (ECTO)
    Meeting Abstract

    Zambetti, M.; Baselga, J.; Eiermann, W.; Guillem, V.; Semiglazov, V.; Lluch, A.; Sabadell, D.; Bozhok, A.; Byakhov, M. J.; Ojeda, B.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Effective incorporation of biospecimen collection for translational studies into a phase III trial: The NeoALTTO experience (BIG 01-06)
    Meeting Abstract

    Nuciforo, P.; Jimenez, J.; Aura, C.; Fumagalli, D.; Maetens, M.; Prudkin, L.; Rothe, F.; Vazquez, J.; Loi, S.; Eidtmann, H.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Incidence, management, and resolution of noninfectious pneumonitis in BOLERO-2
    Meeting Abstract

    Ito, Y.; Noguchi, S.; Deleu, I.; Baselga, J.; Hortobagyi, G. N.; Bachelot, T. D.; Masuda, N.; Pistilli, B.; Pritchard, K. I.; Iwata, H.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Ph III randomized studies of the oral pan-PI3K inhibitor buparlisib (BKM120) with fulvestrant in postmenopausal women with HR+/HER2- locally advanced or metastatic breast cancer (BC) after aromatase inhibitor (AI; BELLE-2) or AI and mTOR inhibitor (BELLE-3) treatment
    Meeting Abstract

    Iwata, H.; Baselga, J.; Campone, M.; Arteaga, C. L.; Cortes, J.; Jonat, W.; De Laurentiis, M.; Ciruelos, E.; Janni, W.; Bachelot, T.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Combination of a MEK inhibitor, pimasertib (MSC1936369B), and a PI3K/mTOR inhibitor, SAR245409, in patients with advanced solid tumors: Results of a phase Ib dose-escalation trial
    Meeting Abstract

    Heist, R. S.; Gandhi, L.; Shapiro, G.; Rizvi, N. A.; Burris, H. A.; Bendell, J. C.; Baselga, J.; Yerganian, S. B.; Hsu, K.; Ogden, J.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Safety, pharmacokinetics, and preliminary activity of the α-specific PI3K inhibitor BYL719: Results from the first-in-human study
    Meeting Abstract

    Gonzalez-Angulo, A. M.; Juric, D.; Argilés, G.; Schellens, J. H. M.; Burris, H. A.; Berlin, J.; Middleton, M. R.; Schuler, M. H.; Van Geel, R.; Helgason, T.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Follow-up results of NOAH, a randomized phase III trial evaluating neoadjuvant chemotherapy with trastuzumab (CT+H) followed by adjuvant H versus CT alone, in patients with HER2-positive locally advanced breast cancer
    Meeting Abstract

    Gianni, L.; Eiermann, W.; Semiglazov, V.; Manikhas, A.; Lluch, A.; Tjulandin, S.; Zambetti, M.; Vazquez, F.; Byakhov, M. J.; Lichinitser, M.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save